Business Wire

New LabVantage Forensic Navigator™ Seamlessly Manages Vast Data Flows Over the Entire Forensic Life Cycle

Share

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS solutions that allow labs to go live faster and at a lower total cost, today announced the introduction of LabVantage Forensic NavigatorTM, an industry expert-built informatics platform designed to seamlessly manage the vast amounts of forensic evidence and data used throughout the entire criminal justice life cycle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005012/en/

Forensic Navigator handles data flows in real time, from the evidence gathered at the crime scene through the ultimate resolution of the investigation. It accelerates the investigative process by streamlining, connecting, and analyzing all aspects of a criminal case, including evidence collection, property management, forensic lab analyses, medical examiner processes and reports, investigative activities, and legal proceedings. Forensic Navigator also includes critical tools to ensure quality management and regulatory compliance, in addition to forensic intelligence capabilities that allow users to gain insight from all data generated spanning investigations even across cases.

“LabVantage Forensic Navigator is a breakthrough informatics platform designed to increase the efficiency, effectiveness and accuracy of criminal justice operations,” said Mikael Hagstroem, Chief Executive Officer of LabVantage Solutions. “Forensic Navigator is built on the foundation of our industry-leading LIMS platform, but our developers went beyond those capabilities to produce a comprehensive system capable of managing and integrating the enormous amount of information generated during criminal investigations. At LabVantage we aim to bring the benefits of digital transformation to a variety of data-intensive industries, and we are proud to introduce this important new product purpose-built for the criminal justice sector, where data abounds and the stakes are so high.”

Forensic Navigator uses browser-based technology that is cloud hosted and is available in either SaaS or on-premise formats. It is a single, integrated, configurable platform that eliminates the need for customization. Forensic Navigator supports compliance with ISO17025, CALEA and other accreditations. It encompasses the entire forensic life cycle with best-in-class cybersecurity protection. Forensic Navigator’s forensics intelligence software provides insights from investigative data and is enhanced by predictive analysis through its forensic intelligence capabilities.

Robin MacDonald, PhD, Senior Product Specialist at LabVantage, spent more than a decade managing a forensic unit serving one of the largest counties in Florida. Dr. MacDonald noted, “The comprehensive data management capabilities of LabVantage Forensic Navigator would have been a huge help when I was a front-line forensic scientist at a busy law enforcement agency. In the complex, highly regulated criminal justice environment, Forensic Navigator’s ability to seamlessly manage all the evidence and data needed for investigations is a major advantage, eliminating the burden and inefficiency of implementing, maintaining, and coordinating multiple data management systems. It allows law enforcement personnel to enter data in real time, make examination requests and check status from a secure web-based portal. We offer a go-live plan that simplifies implementation and LabVantage’s track record of exceptional customer service means that expert user support is always available.”

Key advantages of LabVantage Forensic Navigator include:

  • Advanced technology - HTML5-based platform with advanced predictive analytics via forensic intelligence.
  • Browser-based - Cloud hosted and available in either SaaS or on-premise formats.
  • Configurable - With industry best practices, including data integrity and cybersecurity protection.
  • Online portal - For evidence pre-log, exam requests, status updates, and released reports.
  • Dashboards - View all key performance indicators at a glance.
  • Instruments - Integration and interface with most networkable instruments.
  • Collaboration - Enables rapid access to shared data. Duplicative entry is never needed.
  • Chain of custody - Includes person-to-person and person-to-secure-location transfers, with reporting options.
  • Case management – Facilitates organizing all aspects of the case.
  • Crime scene – Upload images and videos, capture scene-processing activities, and generate reports.
  • Property management – Easily locate evidence and manage disposition activities.
  • Medical examiner - Document external and autopsy observations, track next-of-kin, capture interviews.
  • Laboratory – Track evidence through intake, examination assignment, testing, and reporting.
  • Electronic lab notebook - Tracking support throughout the entire analytical life cycle.
  • Reagents - Manage reagents, standards, and other laboratory consumables.
  • Forensic intelligence - Pool siloed data for rapid resolution of cases and confidence in results.
  • SDMS - Collect and secure files maintained throughout the lab with full traceability and search functions.

For more information on LabVantage Forensic Navigator click here or email info@labvantage.com.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. The LabVantage informatics platform is highly configurable, integrated across a common architecture, and 100% browser-based to support hundreds of concurrent users. Deployed on-premise, via the cloud, or SaaS, it seamlessly interfaces with instruments and other enterprise systems – enabling true digital transformation. The platform consists of the most modern laboratory information management system (LIMS) available, integrated electronic laboratory notebook (ELN), laboratory execution system (LES), scientific data management system (SDMS), and advanced analytics; and, for healthcare settings, a laboratory information system (LIS). We support more than 1500 global customer sites in the life sciences, pharmaceutical, medical device, biobank, food & beverage, consumer packaged goods, oil & gas, genetics/diagnostics, and healthcare industries. Headquartered in Somerset, NJ, with global offices, LabVantage has offered its comprehensive portfolio of products and services to enable customers to innovate faster in the R&D cycle, improve manufactured product quality, achieve accurate record-keeping, and comply with regulatory requirements for four decades. For more information, visit labvantage.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Brandwidth Solutions LLC
Chris Anderson
Phone: 207-232-7007
Email: canderson@BWSmarketing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye